REGEnLIFE
PrivateLast Round
Series A
May 9, 2023
Total Funding Raised
$6.6M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
REGEnLIFE operates in Healthcare & Life Sciences and is based in Paris. Its latest recorded funding round was a Series A round in May 2023.
REGEnLIFE is a therapeutic devices company that develops a non-invasive medical device designed to alter the progression of neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
REGEnLIFE Comparables
Compare REGEnLIFE with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NeuroEM Therapeutics | 81% | |
| Neurocia SAS | 80% | |
| Cognito Therapeutics | 79% |
For institutional investors. Book with your work email.
REGEnLIFE Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 9, 2023 | ||||
| Seed | Jul 10, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 50% MoM.
- Jun 17, 2026
Monthly visitors increased 52% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresAug 22, 2026
On Jul 15th '26 in France, REGEnLIFE appoints Dr. Volker Herrmann as CEO to lead its next strategic phase and global expansion.
- expands_facilitiesAug 22, 2026
REGEnLIFE opens a clinical research centre at Biofortis in Nantes to support Alzheimer's disease research.
For institutional investors. Book with your work email.
REGEnLIFE Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about REGEnLIFE's valuation, stock price, and market status.
Is REGEnLIFE a public or private company?
REGEnLIFE is a private company.
What is the current stock price of REGEnLIFE?
REGEnLIFE is a private company, so its shares have no public market price. Caplight tracks REGEnLIFE's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is REGEnLIFE worth (valuation)?
Valuation information for REGEnLIFE is not publicly available.
Can I buy REGEnLIFE stock?
REGEnLIFE shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was REGEnLIFE's last funding round?
REGEnLIFE's most recent funding round was Series A on May 9, 2023.
Who are the main investors in REGEnLIFE?
Investor information for REGEnLIFE is not publicly disclosed.
Will REGEnLIFE IPO soon?
No public IPO plans have been announced for REGEnLIFE.
How can I track REGEnLIFE secondary market activity?
Caplight tracks bids, offers, and trades in REGEnLIFE's shares on secondary markets.